• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Current epidemiology of chronic liver disease.慢性肝病的当前流行病学。
Gastroenterol Rep (Oxf). 2024 Jun 24;12:goae069. doi: 10.1093/gastro/goae069. eCollection 2024.
2
MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options.与代谢相关脂肪性肝病相关的肝细胞癌:趋势、病理生理学、肿瘤微环境、监测及治疗选择的综合综述
Curr Issues Mol Biol. 2024 Jun 13;46(6):5965-5983. doi: 10.3390/cimb46060356.
3
Current status and future trends of the global burden of MASLD.全球 MASLD 负担的现状和未来趋势。
Trends Endocrinol Metab. 2024 Aug;35(8):697-707. doi: 10.1016/j.tem.2024.02.007. Epub 2024 Feb 29.
4
Changes in the epidemiological trends of primary liver cancer in the Asia-Pacific region.亚太地区原发性肝癌的流行病学趋势变化。
Sci Rep. 2024 Aug 22;14(1):19544. doi: 10.1038/s41598-024-70526-z.
5
Metabolic Dysfunction-associated Steatotic Liver Disease is Becoming the Leading Driver of the Burden of Cirrhosis in China: Results From the Global Burden of Disease Study 2019.代谢功能障碍相关脂肪性肝病正成为中国肝硬化负担的主要驱动因素:2019年全球疾病负担研究结果
J Clin Gastroenterol. 2024 Aug 5. doi: 10.1097/MCG.0000000000002055.
6
Alcohol-associated liver disease-Global epidemiology.酒精性肝病——全球流行病学
Hepatology. 2024 Dec 1;80(6):1307-1322. doi: 10.1097/HEP.0000000000000899. Epub 2024 Apr 19.
7
Epidemiology of liver diseases: global disease burden and forecasted research trends.肝脏疾病流行病学:全球疾病负担及预测的研究趋势
Sci China Life Sci. 2025 Feb;68(2):541-557. doi: 10.1007/s11427-024-2722-2. Epub 2024 Oct 16.
8
Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States.美国 COVID-19 大流行前后基于病因的慢性肝病死亡率趋势。
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2307-2316.e3. doi: 10.1016/j.cgh.2022.05.045. Epub 2022 Jul 8.
9
Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.新冠疫情对美国肝病相关死亡率的影响。
J Hepatol. 2023 Jan;78(1):16-27. doi: 10.1016/j.jhep.2022.07.028. Epub 2022 Aug 18.
10
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.2型糖尿病与代谢功能障碍相关脂肪性肝病的流行病学、筛查及联合管理
Hepatology. 2024 May 8. doi: 10.1097/HEP.0000000000000913.

引用本文的文献

1
The Significance of the Presence of Gilbert's Syndrome in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Retrospective Cohort Study.吉尔伯特综合征在代谢功能障碍相关脂肪性肝病(MASLD)患者中的意义:一项回顾性队列研究
Cureus. 2025 May 30;17(5):e85074. doi: 10.7759/cureus.85074. eCollection 2025 May.
2
Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease.白蛋白血小板产物作为慢性丙型肝炎相关肝病患者无创纤维化分期工具的验证
Sci Rep. 2025 Jun 23;15(1):20265. doi: 10.1038/s41598-025-07456-x.
3
Aggregate index of systemic inflammation tied to increased fatty liver disease risk: insights from NHANES data.与脂肪肝疾病风险增加相关的全身炎症综合指数:来自美国国家健康与营养检查调查(NHANES)数据的见解
BMC Gastroenterol. 2025 May 23;25(1):399. doi: 10.1186/s12876-025-03998-6.
4
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".2019冠状病毒病大流行之前及期间脂肪性肝病的负担:致关于“2017 - 2023年美国成年人脂肪性肝病和肝纤维化的当前负担”的社论的信函
Clin Mol Hepatol. 2025 Apr;31(2):e183-e185. doi: 10.3350/cmh.2025.0152. Epub 2025 Feb 17.
5
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".应对脂肪性肝病负担:瞬时弹性成像的作用:致关于“2017 - 2023年美国成年人脂肪性肝病和纤维化的当前负担”的社论的信
Clin Mol Hepatol. 2025 Apr;31(2):e180-e182. doi: 10.3350/cmh.2025.0125. Epub 2025 Feb 13.
6
Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B.并存的脂肪性肝病与慢性乙型肝炎患者的长期肝脏相关事件无关。
Gastroenterol Rep (Oxf). 2025 Feb 12;13:goaf013. doi: 10.1093/gastro/goaf013. eCollection 2025.
7
Body composition differences in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.代谢功能障碍相关脂肪性肝病患者的身体成分差异
Front Nutr. 2024 Nov 5;11:1490277. doi: 10.3389/fnut.2024.1490277. eCollection 2024.
8
Chronic hepatitis B: Prevent, diagnose, and treat before the point of no return.慢性乙型肝炎:在不可逆转之前进行预防、诊断和治疗。
World J Hepatol. 2024 Oct 27;16(10):1151-1157. doi: 10.4254/wjh.v16.i10.1151.
9
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.瘦人群与非瘦人群中代谢功能障碍相关脂肪性肝病的长期结局及风险修饰因素
Clin Mol Hepatol. 2025 Jan;31(1):74-89. doi: 10.3350/cmh.2024.0631. Epub 2024 Oct 23.
10
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults.2012年至2022年韩国成年人对病毒性肝炎的当代认知情况。
Clin Mol Hepatol. 2025 Jan;31(1):e5-e7. doi: 10.3350/cmh.2024.0849. Epub 2024 Oct 8.

本文引用的文献

1
Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.美国脂肪变性肝病相关全因/病因特异性死亡率。
Aliment Pharmacol Ther. 2024 Jul;60(1):33-42. doi: 10.1111/apt.18011. Epub 2024 Apr 22.
2
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
3
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.美国HIV感染者中脂肪性肝病、代谢相关脂肪性肝病、代谢性酒精性肝病及显著肝纤维化的患病率。
Aliment Pharmacol Ther. 2024 Mar;59(5):666-679. doi: 10.1111/apt.17849. Epub 2023 Dec 29.
4
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories.调整后估计 25 个国家和地区的丁型肝炎病毒流行率。
J Hepatol. 2024 Feb;80(2):232-242. doi: 10.1016/j.jhep.2023.10.043. Epub 2023 Nov 27.
5
Chronic liver disease-related mortality during the COVID-19 pandemic.新冠疫情期间慢性肝病相关死亡率
Eur J Intern Med. 2023 Dec;118:129-132. doi: 10.1016/j.ejim.2023.09.024. Epub 2023 Sep 29.
6
Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States.美国成年人中代谢功能障碍相关脂肪性肝病与全因/特定病因死亡率
J Hepatol. 2024 Feb;80(2):e79-e81. doi: 10.1016/j.jhep.2023.09.014. Epub 2023 Sep 16.
7
Depression in nonalcoholic fatty liver disease and all-cause/cause-specific mortality.非酒精性脂肪性肝病中的抑郁与全因/特定病因死亡率
Eur J Clin Invest. 2024 Jan;54(1):e14087. doi: 10.1111/eci.14087. Epub 2023 Aug 28.
8
Can we use old NAFLD data under the new MASLD definition?在新的代谢相关脂肪性肝病(MASLD)定义下,我们能否使用旧的非酒精性脂肪性肝病(NAFLD)数据?
J Hepatol. 2024 Feb;80(2):e54-e56. doi: 10.1016/j.jhep.2023.07.021. Epub 2023 Aug 2.
9
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.2022年全球乙型肝炎的流行率、照护流程及预防覆盖率:一项建模研究
Lancet Gastroenterol Hepatol. 2023 Oct;8(10):879-907. doi: 10.1016/S2468-1253(23)00197-8. Epub 2023 Jul 27.
10
Trends in mortality of liver cancer before and during the COVID-19 pandemic, 2017-2021.2017-2021 年 COVID-19 大流行前后肝癌死亡率趋势。
Liver Int. 2023 Sep;43(9):1865-1870. doi: 10.1111/liv.15668. Epub 2023 Jun 30.

慢性肝病的当前流行病学。

Current epidemiology of chronic liver disease.

作者信息

Manikat Richie, Ahmed Aijaz, Kim Donghee

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

Gastroenterol Rep (Oxf). 2024 Jun 24;12:goae069. doi: 10.1093/gastro/goae069. eCollection 2024.

DOI:10.1093/gastro/goae069
PMID:38915345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11194530/
Abstract

Chronic liver disease presents a significant global health burden, characterized by several etiologies, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), chronic hepatitis B virus infection, and chronic hepatitis C virus infection. This review explored current epidemiological trends and projections for each etiology, looking into their respective burdens and challenges. MASLD, formerly known as nonalcoholic fatty liver disease, is the most prevalent cause of chronic liver disease, and its global incidence and prevalence are steadily rising. ALD, fueled by increased alcohol consumption, is also on the rise, with concerning implications for future mortality rates. Chronic hepatitis B and C infections remain major public health concerns, particularly in specific regions of the world, necessitating concerted efforts for screening and treatment. The coronavirus disease 2019 (COVID-19) pandemic has impacted the epidemiology of chronic liver disease, exacerbating mortality rates and disrupting healthcare services. Mental health issues arising from the pandemic further complicate the treatment of chronic liver disease, making comprehensive healthcare strategies essential. Despite advancements in treatment, chronic liver disease continues to impose a substantial economic burden, emphasizing the importance of preventive measures and early intervention. In conclusion, ongoing surveillance and research efforts are crucial for understanding and addressing the evolving landscape of chronic liver disease. Comprehensive strategies that encompass prevention, screening, and treatment of its different etiologies are essential for mitigating its impact and improving patient outcomes.

摘要

慢性肝病是一项重大的全球健康负担,其病因多样,包括代谢功能障碍相关脂肪性肝病(MASLD)、酒精性肝病(ALD)、慢性乙型肝炎病毒感染和慢性丙型肝炎病毒感染。本综述探讨了每种病因的当前流行病学趋势和预测,研究了它们各自的负担和挑战。MASLD,前身为非酒精性脂肪性肝病,是慢性肝病最常见的病因,其全球发病率和患病率正在稳步上升。由于酒精消费增加,ALD也在上升,对未来死亡率有令人担忧的影响。慢性乙型和丙型肝炎感染仍然是主要的公共卫生问题,特别是在世界的特定地区,需要齐心协力进行筛查和治疗。2019年冠状病毒病(COVID-19)大流行影响了慢性肝病的流行病学,加剧了死亡率并扰乱了医疗服务。大流行引发的心理健康问题使慢性肝病的治疗更加复杂,因此全面的医疗保健策略至关重要。尽管治疗取得了进展,但慢性肝病继续带来巨大的经济负担,这凸显了预防措施和早期干预的重要性。总之,持续的监测和研究工作对于理解和应对慢性肝病不断变化的形势至关重要。涵盖其不同病因的预防、筛查和治疗的综合策略对于减轻其影响和改善患者结局至关重要。